Transgender Women Living with HIV Frequently Take Antiretroviral Therapy and/or Feminizing Hormone Therapy Differently Than Prescribed Due to Drug-Drug Interaction Concerns.
LGBT Health
; 4(5): 371-375, 2017 10.
Article
em En
| MEDLINE
| ID: mdl-28876170
ABSTRACT
PURPOSE:
Both hormone therapy (HT) and antiretroviral therapy (ART) can be lifesaving for transgender women (TW) living with HIV, but each has side effects and potential drug-drug interactions (DDI). We assessed how concerns about HT-ART interactions affect treatment adherence.METHODS:
This study used a cross-sectional survey of TW (n = 87) in Los Angeles, CA.RESULTS:
Fifty-four percent were living with HIV; 64% used HT. Only 49% of TW living with HIV discussed ART-HT DDI with their provider; 40% reported not taking ART (12%), HT (12%), or both (16%) as directed due to DDI concerns.CONCLUSION:
Imperfect HT/ART use and limited provider communication suggests a need for improved HT-ART integration.Palavras-chave
Texto completo:
1
Coleções:
01-internacional
Base de dados:
MEDLINE
Assunto principal:
Infecções por HIV
/
Fármacos Anti-HIV
/
Terapia de Reposição Hormonal
/
Interações Medicamentosas
/
Adesão à Medicação
/
Pessoas Transgênero
Tipo de estudo:
Observational_studies
/
Prevalence_studies
/
Risk_factors_studies
Limite:
Female
/
Humans
/
Male
/
Middle aged
País/Região como assunto:
America do norte
Idioma:
En
Revista:
LGBT Health
Ano de publicação:
2017
Tipo de documento:
Article